Oncorus Inc (ONCR)

NASDAQ
5.83
+0.03(+0.52%)
  • Volume:
    98,738
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    5.79 - 6.06

ONCR Overview

Prev. Close
5.8
Day's Range
5.79-6.06
Revenue
-
Open
5.83
52 wk Range
5.29-37.86
EPS
-2.32
Volume
98,738
Market Cap
154.34M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
205,120
P/E Ratio
-
Beta
-
1-Year Change
-80.38%
Shares Outstanding
25,809,006
Next Earnings Date
Mar 09, 2022
What is your sentiment on Oncorus Inc?
or
Vote to see community's results!

Oncorus Inc Company Profile

Employees
56

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company’s lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck’s cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuySellSell
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuyStrong Sell
SummaryStrong SellSellStrong BuyNeutralStrong Sell
  • Sell, Sell, Sell… Time to buy?
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.